Amylyx Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities
Amylyx Pharmaceuticals, Inc. (AMLX) reported Increase (Decrease) in Accrued Liabilities of -$3.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $3.18M, a 41.09% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$6.67M.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$1.21M.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $1.09M.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$6.60M.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$59.81M, a 376.94% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $21.60M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.49M 10-Q · filed 2026-08-06 | -$4.70M derived: sum of 3 quarters · filed 2026-08-06 | -$3.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$6.67M 10-Q · filed 2026-05-07 | -$7.88M derived: sum of 2 quarters · filed 2026-05-07 | -$6.79M derived: sum of 3 quarters · filed 2026-05-07 | -$1.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$114.00K derived: sum of 2 quarters · filed 2026-03-03 | $5.28M derived: sum of 3 quarters · filed 2026-08-06 | -$6.60M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.49M derived: sum of 2 quarters · filed 2026-08-06 | -$5.39M 10-Q · filed 2025-11-06 | -$31.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$6.48M 10-Q · filed 2026-08-06 | -$32.88M derived: sum of 3 quarters · filed 2026-08-06 | -$45.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$11.88M 10-Q · filed 2026-05-07 | -$38.28M derived: sum of 2 quarters · filed 2026-05-07 | -$51.39M derived: sum of 3 quarters · filed 2026-05-07 | -$63.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$26.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$39.51M derived: sum of 2 quarters · filed 2026-03-03 | -$52.03M derived: sum of 3 quarters · filed 2026-03-03 | -$59.81M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$13.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$25.64M derived: sum of 2 quarters · filed 2025-11-06 | -$33.41M 10-Q · filed 2025-11-06 | -$12.64M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$12.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$20.30M 10-Q · filed 2025-08-07 | $467.00K derived: sum of 3 quarters · filed 2025-08-07 | $321.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$7.78M 10-Q · filed 2025-05-08 | $13.00M derived: sum of 2 quarters · filed 2025-05-08 | $12.85M derived: sum of 3 quarters · filed 2025-05-08 | $11.64M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $20.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $20.63M derived: sum of 2 quarters · filed 2025-03-04 | $19.42M derived: sum of 3 quarters · filed 2025-03-04 | $21.60M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.35M derived: sum of 2 quarters · filed 2024-11-07 | $825.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $971.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $2.18M 10-Q · filed 2024-05-09 | |||
| 2022-09-30 | $5.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $7.69M derived: sum of 2 quarters · filed 2023-11-09 | $10.44M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $4.78M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $2.74M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |